Covidien's Q4 profits hit by spin-out costs
This article was originally published in Clinica
Despite recording a 5% increase in group sales for the fourth quarter of fiscal 2007, Covidien was unable to prevent higher-than-expected expenses from impacting overall profits. The company saw total earnings fall from $340m for the same period in 2006 to $34m, after it was hit by $697m worth of selling, general and administrative expenses and $290m of charges related to its spin-out from Tyco International earlier this year (see Clinica No 1244, p 12).
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.